Background Human immunodeficiency virus (HIV) infection is the strongest risk factor for
developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In …

HPTN 052 required many years of preparation, considerable collaboration between
National Institute of Health and six pharmaceutical companies, and careful ongoing …

Background Data from randomized trials are lacking on the benefits and risks of initiating
antiretroviral therapy in patients with asymptomatic human immunodeficiency virus (HIV) …

Background Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related
morbidity and mortality and prevents sexual transmission of HIV-1. However, the best time to …

Global malaria control efforts have produced remarkable results over the past 15 years. In
2016, there were an estimated 216 million cases of malaria and an estimated 445 000 …

Context New trial data and drug regimens that have become available in the last 2 years
warrant an update to guidelines for antiretroviral therapy (ART) in human immunodeficiency …

Chinese translation Description: Update of the 2005 US Preventive Services Task Force
(USPSTF) recommendation statement on screening for HIV. Methods: The USPSTF …

Antiretroviral drugs that inhibit viral replication were expected to reduce transmission of HIV
by lowering the concentration of HIV in the genital tract. In 11 of 13 observational studies …

Objectives To characterize viro-immunological outcomes following long-term combined
antiretroviral therapy (cART) initiated during primary HIV infection (PHI) or chronic HIV …

Abstract Effect estimates from randomized trials and observational studies might not be
directly comparable because of differences in study design, other than randomization, and in …